Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | GPR39 | O43194 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885608 | 0.83 | HPGD (0.48) | HDAC1HDAC6HDAC3HDAC2KDM4E | |
| Pyridine SCHEMBL3572978 | 0.79 | F2 (0.39) | HDAC1HDAC6HDAC8CYP2C9CYP2C19 | |
| SCHEMBL2883879 | 0.78 | MAOA (0.49) | HDAC1HDAC6HDAC3HDAC2KDM4E | |
| SCHEMBL2884302 | 0.77 | MAPK9 (0.44) | MKNK1KDM4EALDH1A1HPGDMKNK2 | |
| Pyridine SCHEMBL3569017 | 0.76 | KCNH3 (0.44) | KCNH3KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL27512383 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1HPGDLMNAGAA | |
| SCHEMBL2883441 | 0.75 | OGA (0.53) | MKNK1KCNH3ADRA2CKDM4EALDH1A1 | |
| SCHEMBL2881380 | 0.75 | NUDT1 (0.43) | MKNK1KCNH3KDM4EMKNK2MAPT | |
| SCHEMBL2790083 | 0.74 | OGA (0.52) | MKNK1ADRA2CKDM4ECYP1A2CYP2D6 | |
| SCHEMBL2883333 | 0.74 | MKNK1 (0.45) | MKNK1KCNH3KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MKNK1 125/4885KCNH3 1948/4885HDAC1 288/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MKNK1 55/4885KCNH3 2595/4885HDAC1 958/4885 |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | SMAD3, SQOR, TNNI3 | MKNK1 1571/4885KCNH3 1142/4885HDAC1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.